Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

We report here the results of a phase 3 study to assess the efficacy, safety, and tolerability of GC5107, a new 10% liquid intravenous immunoglobulin (IVIG) in preventing serious bacterial infections in patients with primary immunodeficiency (ClinicalTrials.gov: NCT02783482). Over a 12-month study p...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Elena E. Perez, Jacques Hébert, Anne K. Ellis, Oral Alpan, William R. Lumry, Ralph Shapiro, Daniel Suez, J. Fernando Mandujano, Richard L. Wasserman
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2021-07-01
Sarja:	Frontiers in Immunology
Aiheet:	primary immunodeficiency disease inborn errors of immunity immune globulin intravenous intravenous immune globulin immunoglobulin replacement therapy IVIG
Linkit:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.707463/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!